COVID-19 is, in the end, an endothelial disease - PubMed (original) (raw)

Review

COVID-19 is, in the end, an endothelial disease

Peter Libby et al. Eur Heart J. 2020.

Abstract

The vascular endothelium provides the crucial interface between the blood compartment and tissues, and displays a series of remarkable properties that normally maintain homeostasis. This tightly regulated palette of functions includes control of haemostasis, fibrinolysis, vasomotion, inflammation, oxidative stress, vascular permeability, and structure. While these functions participate in the moment-to-moment regulation of the circulation and coordinate many host defence mechanisms, they can also contribute to disease when their usually homeostatic and defensive functions over-reach and turn against the host. SARS-CoV-2, the aetiological agent of COVID-19, causes the current pandemic. It produces protean manifestations ranging from head to toe, wreaking seemingly indiscriminate havoc on multiple organ systems including the lungs, heart, brain, kidney, and vasculature. This essay explores the hypothesis that COVID-19, particularly in the later complicated stages, represents an endothelial disease. Cytokines, protein pro-inflammatory mediators, serve as key danger signals that shift endothelial functions from the homeostatic into the defensive mode. The endgame of COVID-19 usually involves a cytokine storm, a phlogistic phenomenon fed by well-understood positive feedback loops that govern cytokine production and overwhelm counter-regulatory mechanisms. The concept of COVID-19 as an endothelial disease provides a unifying pathophysiological picture of this raging infection, and also provides a framework for a rational treatment strategy at a time when we possess an indeed modest evidence base to guide our therapeutic attempts to confront this novel pandemic.

Keywords: Inflammation; Microvasculature; Thrombosis; Cytokine; Endothelium.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

PubMed Disclaimer

Figures

Figure 1

Figure 1

The left side of the diagram depicts a resting endothelial monolayer with the endothelial cells of squamous morphology resting on an intact basement membrane. The homeostatic mechanisms displayed by the resting endothelium include the listed properties as detailed in the text. When the endothelial cells undergo the cytopathic effect of a viral infection such as SARS-CoV-2, or encounter pathogen-associated molecular patterns (PAMPs) derived from viruses or bacteria such as lipopolysaccharide, proinflammatory cytokines such as IL-1 or TNF, or damage-associated molecular patterns (DAMPs) derived from dead or dying cells, the endothelial cells become activated. The endothelial cells display more columnar morphology. They can express adhesion molecules that attract leucocytes and chemokines that direct their migration into the subendothelial space. Sloughing of endothelial cells uncovers the thrombogenic basement membrane. Adherent neutrophils can undergo formation of neutrophil extracellular traps that provide an amplifier for endothelial damage mediated in part by IL-1α. Inflammatory activation of endothelial cells can disrupt VE-cadherin largely responsible for the integrity of the endothelial barrier function. Activated endothelial cells can also express matrix metalloproteinases that can degrade the basement membrane and further interrupt endothelial barrier function. In small vessels, such as those that embrace alveoli in the lung, this impaired barrier function can lead to capillary leak. These various disturbances in endothelial function, depicted in the middle part of the diagram, lead to end organ damage including adult respiratory distress syndrome and thrombosis in the lungs, predispose to plaque rupture and thrombosis in coronary arteries, and affect the microvasculature leading to myocardial ischaemia and damage. The thrombotic diathesis provoked by endothelial dysfunction can also predispose towards strokes. Microvascular as well macrovascular injury can potentiate acute renal failure. Hepatic dysfunction can also result from microvascular thrombosis among other mechanisms. Deep venous thrombosis can occur as endothelial disfunction represents an important part of Virchow’s triad, and sets the stage for pulmonary embolism. Thus, loss of the endothelial protective and unleashing of the mechanisms depicted can lead to multiorgan system failure that characterizes the advanced stages of COVID-19.

Figure 2

Figure 2

Cytokine storm. Proinflammatory cytokines such as IL-1 and TNF-α induce each other’s gene expression, unleashing an amplification loop that sustains the cytokine storm. The endothelial cell is a key target of cytokines, as they induce action of a central proinflammatory transcriptional hub, nuclear factor-κB. IL-1 also causes substantial increases in production by endothelial and other cells of IL-6, the instigator of the hepatocyte acute phase response. The acute phase reactants include fibrinogen, the precursor of clot, and PAI-1, the major inhibitor of our endogenous fibrinolytic system. C-reactive protein, commonly elevated in COVID-19, provides a readily measured biomarker of inflammatory status. The alterations in the thrombotic/fibrinolytic balance due to the acute phase response promotes thrombosis in arteries, in the microvasculature including that of organs such as the myocardium and kidney, and in veins, causing deep vein thrombosis and predisposing towards pulmonary embolism. Thus, the very same cytokines that elicit abnormal endothelial functions can unleash the acute phase response which together with local endothelial disfunction can conspire to cause the clinical complications of COVID-19. The right side of this diagram aligns therapeutic agents that attack these mechanisms of the cytokine storm and may thus limit its devastating consequences.

Comment in

Similar articles

Cited by

References

    1. Aird WC. Endothelium. In: Kitchens CS, Kessler CM, Konkle BA, eds. Consultative Hemostasis and Thrombosis, 3rd ed. Philadelphia. PA: W.B. Saunders; 2013. p33–41.
    1. Libby P. The vascular biology of atherosclerosis. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, eds. Braunwald’s Heart Disease, 11th ed. Philadelphia, PA: Elsevier; 2018. p859–875.
    1. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007;7:803–815. - PubMed
    1. Libby P. The active roles of cells of the blood vessel wall in health and disease. Mol Aspects Med 1987;9:499–567. - PubMed
    1. Libby P, d Birinyi LK. The dynamic nature of vascular endothelial functions. In: Zilla P, Fasol R, Deutsch M, eds. Endothelialization of Vascular Grafts. Basel: Karger; 1987. p80–99.

Publication types

MeSH terms

Substances

LinkOut - more resources